LeafNLP Demos
Back to explore

Report #2865534

Received Oct 13, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
TX
Recovered
Unknown
Vaccinated
Mar 2, 2025
Onset
Mar 2, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS255TH4—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

first being administered in 11-AUG-2023 and second was given March 2nd, 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number 55TH4, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 11-AUG-2023 Batch no.: 3777F Expiry date: 30-MAY-2024). On 02-MAR-2025, the patient received the 2nd dose of Shingrix. On 02-MAR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first being administered in 11-AUG-2023 and second was given March 2nd, 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 19-SEP-2025 A pharmacist called in to request data about the stability of Shingrix.